Goldman Drops Haleon; Analysts See 18% Upside
Goldman Sachs dropped Haleon from its 25-stock European Conviction List because the company falls short of the 41% total return potential that characterizes stocks on that list. Analysts still forecas
Goldman Drops Haleon; Analysts Still See 18% Upside
NEW YORK, November 4 —
Goldman Sachs removed Haleon plc (HLN) from its European Conviction List, a 25-stock roster with median 12-month upside of 35%, while analysts still see 18% upside from $8.84. The removal frames the question: whether Haleon's $1.8 billion in free cash flow can close that gap, or whether $7.42 billion in net debt and below-forecast revenue growth keep institutional buyers away.
- Net debt $7.42bn = 4.1x trailing FCF of $1,802mn, limiting balance sheet flexibility while revenue grows at 2.2%.
- Goldman's Conviction List carries median 41% total return potential; Haleon was replaced by Deutsche Bank and Carlsberg.
- Consensus analyst target of $10.38 implies 18% upside; Haleon trades at 14.5x forward earnings with 65.6% gross margins.
Defensible, Not Conviction-Worthy
Goldman replaced Haleon with Deutsche Bank and Carlsberg, a pointed contrast: both additions operate in sectors with clearer near-term catalysts than consumer healthcare. The Conviction List carries median 12-month total return potential of 41%; Haleon's analyst target falls well below that bar. The gap between what Goldman demands from its best ideas and what analysts project for Haleon shows the issue is not valuation but velocity. A 14.5x forward P/E looks defensible for a business that sells Sensodyne toothpaste, Centrum vitamins, Advil and Voltaren, but defensible and conviction-worthy are not the same threshold.
2.2% Growth Against a 4.1x Debt Load
Analyst models pencil in 4% annual revenue growth for Haleon; the trailing twelve months delivered 2.2%, and that shortfall compounds against a balance sheet that cannot easily absorb slow growth. Total debt of $8.25 billion against $0.83 billion in cash runs at 4.1 times trailing free cash flow, leaving limited room for misses. With only 14.1% of shares in institutional hands, the stock lacks the forced buying that a re-rating would normally attract. The setup is a classic value trap profile: strong cash generation offset by leverage that keeps intrinsic value from translating into price appreciation.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HLN | $38.9B | 14.6x | -6.0% |
| OGN | $3.6B | 3.8x | +112.0% |
| KVUE | $37.1B | 15.6x | +20.9% |
| VTRS | $21.7B | 7.0x | +78.0% |
| ELAN | $12.3B | 19.3x | +7.1% |
| GSK | $97.6B | 9.8x | +4.9% |
The Number That Changes the Story
The bear case hinges on two clocks running in opposite directions: free cash flow pays down debt, but only if revenue growth accelerates toward the 4% analyst forecast. The number to watch is organic revenue growth in coming quarters; if Haleon posts two consecutive results above 3%, the discount to analyst targets becomes a catalyst story rather than a waiting game. October's Excedrin Rapid Relief launch shows management pushing for share in pain relief, though whether it moves the needle on $11.15 billion in annual revenue remains the test. For the balance sheet detail, run the free Haleon plc deep-dive or stress-test the valuation in the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Goldman remove Haleon from its Conviction List?
Goldman removed Haleon because the company's projected 18% upside falls well below the 41% median total return potential that the bank demands from its Conviction List stocks. While Haleon trades at a defensible 14.5x forward P/E with strong 65.6% gross margins, defensible and conviction-worthy are not the same threshold.
What is Haleon's analyst price target?
The consensus analyst price target for Haleon is $10.38, implying 18% upside from $8.84. This forecast assumes 4% annual revenue growth, though the company delivered only 2.2% growth in the trailing twelve months.
What is Haleon's debt load?
Haleon carries $7.42 billion in net debt equal to 4.1 times its trailing $1.8 billion in free cash flow. This leverage limits balance sheet flexibility while revenue growth trails historical expectations.
What brands does Haleon own?
Haleon manufactures Sensodyne toothpaste, Centrum vitamins, Advil painkillers, and Voltaren anti-inflammatory products. The company generates $11.15 billion in annual revenue from these consumer healthcare brands.
What is the key catalyst to watch?
Organic revenue growth is critical. If Haleon posts two consecutive quarters above 3% growth, the discount to analyst targets becomes a bullish catalyst story rather than a value trap. The company's October launch of Excedrin Rapid Relief signals management's push for market share gains.
Goldman Sachs removed Haleon from its European Conviction List in its November 2026 update, an institutional exit that arrives as the stock already trades roughly 15% below the consensus analyst target of $10.398. The removal directly tests whether Haleon's $1.8 billion in trailing free cash flow can eventually close that gap — or whether a $7.42 billion net debt burden and below-forecast revenue growth will keep institutional buyers on the sidelines.
Sources & Filings